2 weeks Ago
LOS ANGELES , Sept. 17, 2024 /PRNewswire/ -- ImmPACT Bio USA , Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the Cell & Gene Therapy International 2024 meeting, to be held September 23-26, 2024 in Boston, MA.
Sylvain Roy , ImmPACT Bio's chief technology officer, will provide a presentation about cell therapy manufacturing entitled, "Transitioning from Manual to Automated Processing in Autologous CAR T Manufacturing: A Case Study," on Wednesday, September 25, 2024 at 12:00 PM ET . "While the efficacy and durability of autologous CAR T therapies remain unparalleled, a key challenge for scalability and continued adoption is the complexity and cost of manufacturing," said Mr. Roy.
"At this meeting, ImmPACT Bio will present a case study of transition from an established GMP manual process to an automated, closed-processing manufacturing platform, and address key aspects on the optimization of CAR T-cell therapy manufacturing." About ImmPACT Bio ImmPACT Bio USA , Inc., is a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients.
The company's logic-gate-based chimeric antigen receptor (CAR) T-cell platforms, licensed from University of California, Los Angeles ( UCLA ) Technology Development Group, are specifically designed to provide broad B cell depletion, prevent antigen escape, improve cell persistence, and overcome the immunosuppressive tumor microenvironment. The company's technology is based on the work of pioneering scientists, Yvonne Chen, Ph.D.
, and Antoni Ribas , M.D., Ph.
D., both from UCLA . For more information, visit http://www.
immpact-bio.com . SOURCE ImmPACT Bio USA Inc.
.
